Effect of polycystic ovary syndrome on pregnancy outcomes

doi:10.3969/j.issn.1006-7795.2016.04.007

Abstract

Abstract: Polycystic ovary syndrome (PCOS) is a most common endocrine and metabolic disorder in women of reproductive age. Most studies suggest that insulin resistance, hyperandrogenism and obesity play an important role in the pathophysiology of PCOS. Adverse pregnancy and neonatal outcomes, such as Gestational diabetes mellitus, pregnancy-induced hypertension, are always observed clinically. Therefore, we review the relative factors about adverse outcomes, for example, the development competence of follicles and embryos, the endometrial receptivity in PCOS women, and the relationship between PCOS and pregnancy complications, in order to investigate the effects of preconceptional anti-androgenic treatment on pregnancy outcomes.

Key words: polycystic ovary syndrome, hyperandrogenism, insulin resistance, development of follicle, pregnant outcomes

CLC Number:

R711.75

Li Yanglu, Ruan Xiangyan, Alfred O. Mueck. Effect of polycystic ovary syndrome on pregnancy outcomes[J]. Journal of Capital Medical University, 2016, 37(4): 449-453.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I4/449

References

[1] Fauser B C, Tarlatzis B C, Rebar R W, et al. Consensus on women's health aspectsof polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J]. Fertil Steril, 2012,97(1):28-38.
[2] Naver K V, Grinsted J, Larsen S O, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia[J]. BJOG, 2014, 121(5):575-581.
[3] Aktun H L, Yorgunlar B, Acet M, et al. The effects of polycystic ovary syndrome on gestational diabetes mellitus[J]. Gynecol Endocrinol, 2016,32(2):139-142.
[4] Qin J Z, Pang L H, Li M J, et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Reprod Biol Endocrinol, 2013, 11:56.
[5] Ehrmann D A. Polycystic ovary syndrome[J]. N Engl J Med, 2005,352(12):1223-1236.
[6] Tsilchorozidou T, Overton C, Conway G S. The pathophysiology of polycystic ovary syndrome[J]. Clin Endocrinol (Oxf), 2004, 60(1):1-17.
[7] Legro R S, Castracane V D, Kaufmann R P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls[J]. Obstet Gynecol Surv,2004,59(2):141-154.
[8] Bates G W Jr, Propst A M. Polycystic ovarian syndrome management options[J]. Obstet Gynecol Clin North Am, 2012,39(4):495-506.
[9] Chang R J, Cook-Andersen H. Disordered follicle development[J]. Mol Cell Endocrinol, 2013,373(1-2):51-60.
[10] Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome[J]. Hum Reprod Update,2008,14(4):367-378.
[11] Dewailly D, Catteau-Jonard S, Reyss A C, et al. Oligoanovulation and polycystic ovaries but no overt hyperandrogenism[J]. J Clin Endocrinol Metab,2006,91(10): 3922-3927.
[12] Pierre A, Peigneé M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome[J]. Hum Reprod,2013,28(3):762-769.
[13] Urman B, Tiras B, Yakin K. Assisted reproduction in the treatment of polycystic ovarian syndrome[J]. Reprod Biomed Online, 2004,8(4):419-430.
[14] Kurzawa R, Ciepiela P, Baczkowski T,et al. Comparison of embryological and clinical outcome in GnRH antagonist vs GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study[J]. J Assist Reprod Genet, 2008,25(8):365-374.
[15] Jungheim E S, Schoeller E L, Marquard K L, et al. Diet-induced obesity model: abnormal oocytes and persistent growth abnormalities in the offspring[J]. Endocrinology, 2010, 151(8):4039-4046.
[16] Niu Z, Lin N, Gu R, et al. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization[J]. J Clin Endocrinol Metab, 2014, 99(11):E2269-E2276.
[17] Qiao J, Feng H L. Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011,17(1):17-33.
[18] Giudice L C.Endometrium in PCOS: Implantation and predisposition to endocrine CA[J]. Best Pract Res Clin Endocrinol Metab, 2006, 20(2):235-244.
[19] Taylor A H, Guzail M, Wahab M, et al. Quantitative histomorphometric analysis of gonadal steroid receptor distribution in the normal human endometrium through the menstrual cycle[J]. Histochem Cell Biol, 2005,123(4-5):463-474.
[20] Villavicencio A, Bacallao K, Avellaira C, et al. Androgen and estrogen receptors and co-regulators levels in endometrial from patients with polycystic ovarian syndrome with and without endometrial hyperplasia[J].Gynecol Oncol, 2006, 103(1):307-314.
[21] Berstein L M,Kvatchevskaya J O,Poroshina T E, et al. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer[J]. J Cancer Res Clin Oncol, 2004, 130(11): 687-693.
[22] 翟军,孙莹璞,刘春喜,等. 二甲双胍治疗对PCOS 患者子宫内膜胰岛素抵抗的影响[J].河南医学研究,2012, 21(1):26-31.
[23] Wang Y, Zhao X, Zhao H, et al. Risks for gestational diabetes mellitus and pregnancy-induced hypertension are increased in polycystic ovary syndrome[J]. Biomed Res Int, 2013, 2013:182582.
[24] Chen M J, Yang W S, Yang J H, et al. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome[J]. Hypertension, 2007,49(6):1442-1447.
[25] Naver K V, Grinsted J, Larsen S O, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia[J]. BJOG, 2014,121(5):575-581.
[26] Veltman-Verhulst S M, van Haeften T W, Eijkemans M J, et al. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome[J]. Hum Reprod, 2010,25(12):3123-3128.
[27] Ecklund L C, Usadi R S. Endocrine and reproductive effects of polycystic ovarian syndrome[J]. Obstet Gynecol Clin North Am, 2015,42(1):55-65.
[28] Pan J X, Liu Y, Ke Z H, et al. Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess[J]. Gynecol Endocrinol, 2015,31(4):332-336.
[29] 卢永军,阮祥燕,田玄玄,等.多囊卵巢综合征综合治疗对妊娠结局的影响[J]. 2014,35(4):428-432.
[30] Palomba S, Falbo A, Orio F Jr, et al. Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation[J]. Fertil Steril,2008,89(6):1838-1842.